Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv 2017 Aug 22;1(19):1533-1536
Date
01/04/2018Pubmed ID
29296794Pubmed Central ID
PMC5728466DOI
10.1182/bloodadvances.2017007526Scopus ID
2-s2.0-85040141428 (requires institutional sign-in at Scopus site) 109 CitationsAbstract
Optimal salvage therapy for refractory HLH is unknown.In our patient, ruxolitinib treatment led to clinical remission of refractory HLH.
Author List
Broglie L, Pommert L, Rao S, Thakar M, Phelan R, Margolis D, Talano JAuthors
Larisa Broglie MD, MS Associate Professor in the Pediatrics department at Medical College of WisconsinDavid A. Margolis MD Chair, Professor in the Pediatrics department at Medical College of Wisconsin
Rachel A. Phelan MD, MPH Associate Professor in the Pediatrics department at Medical College of Wisconsin
Sridhar Rao MD, PhD Associate Professor in the Pediatrics department at Medical College of Wisconsin
Julie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin
